In recent years, with the widely application of carbapenems, carbapenem-resistant Enterobacterales (CRE) infection is increasingly prevalent in children, and are often associated with poor clinical outcomes. Due to the specific pharmacokinetic/pharmacodynamic (PK/PD) characteristics of children, most anti-CRE antimicrobial agents lack clinical application experience in children, and pediatricians face huge challenge in the treatment of CRE. In this paper, the existing knowledge of CRE infection in children is collected, epidemiology, antimicrobial resis-tance mechanisms and the latest treatment strategies are reviewed, so as to provide a reference for clinical medication.